title: Addition of ibuprofen to pseudoephedrine and chlorpheniramine in the treatment of seasonal allergic rhinitis.
abstract: BACKGROUND
  Patients with seasonal allergic rhinitis experience many nasal and concomitant nonnasal symptoms. Many patients also experience headaches and facial pain, pressure, or discomfort. Standard over-the-counter therapy with antihistamines and nasal decongestants often does not completely relieve all symptoms associated with allergic rhinitis.
  
  
  OBJECTIVE
  To establish the contribution of ibuprofen when used with pseudoephedrine and chlorpheniramine, a standard over-the-counter regimen, to relieve the symptoms of seasonal allergic rhinitis.
  
  
  METHODS
  In this 7-day, multicenter, randomized, placebo-controlled, double-blind, double-dummy, parallel-group trial, qualified subjects were randomly assigned to 1 of 4 treatment groups that received combined ibuprofen/pseudoephedrine/chlorpheniramine (200/30/2 mg or 400/60/4 mg), combined pseudoephedrine/chlorpheniramine (30/2 mg), or placebo. Therapy began when the subject experienced a minimum of moderate allergy-associated pain, and it continued 3 times a day for 7 consecutive days.
  
  
  RESULTS
  Mean pain intensity reduction in both ibuprofen/pseudoephedrine/chlorpheniramine treatment groups was 40% greater than in the placebo group and 33% greater than in the pseudoephedrine/chlorpheniramine treatment group (P < .001). Mean changes from baseline in total and nonpain symptom scores for both ibuprofen/pseudoephedrine/chlorpheniramine doses were significantly greater than for placebo (P < .001) and pseudoephedrine/chlorpheniramine (P < .001-.05) but were not different from each other. Ibuprofen enhanced the chlorpheniramine and pseudoephedrine effects, resulting in incremental 33% to 34% pain relief and 17% to 22% allergy symptom relief compared with pseudoephedrine/chlorpheniramine.
  
  
  CONCLUSIONS
  In both doses of the triple combination, ibuprofen added to the effects of chlorpheniramine and pseudoephedrine, resulting in superior relief of pain and all nonpain allergy symptoms compared with pseudoephedrine/chlorpheniramine treatment. Furthermore, the superior efficacy of the lower dose of the triple combination allowed for a decrease in the incidence of adverse effects.
authors.affiliation: Allergy & Asthma Medical Group & Research Center, San Diego, California, USA.
authors.forename: Eli O
authors.initials: EO
authors.lastname: Meltzer
authors.forename: Gary D
authors.initials: GD
authors.lastname: Berman
authors.forename: Jonathan
authors.initials: J
authors.lastname: Corren
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Pedinoff
authors.forename: Geraldine
authors.initials: G
authors.lastname: Doyle
authors.forename: Joel A
authors.initials: JA
authors.lastname: Waksman
authors.forename: Paul
authors.initials: P
authors.lastname: Butkerait
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Cooper
authors.forename: Roger G
authors.initials: RG
authors.lastname: Berlin
authors.forename: Suman
authors.initials: S
authors.lastname: Wason
mesh_terms: D000328:Adult; D002744:Chlorpheniramine / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004809:Ephedrine / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007052:Ibuprofen / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*
chemical_list: D002744:Chlorpheniramine; D004809:Ephedrine; D007052:Ibuprofen